
Efficacy of Combined Pembrolizumab and Bevacizumab in Platinum-Resistant Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is common in South China and parts of Southeast Asia. Despite treatment, 20-30% of patients relapse within five years and ultimately become resistant to standard platinum-based chemotherapy;








